The stock of West Pharmaceutical Services, Inc (NYSE: WST) has increased by 2.13 when compared to last closing price of 327.01.Despite this, the company has seen a gain of 1.18% in its stock price over the last five trading days. zacks.com reported 2024-12-20 that WST continues to gain momentum due to its strength in the Pharma market unit. However, the decline across its Generics and Biologics business units is concerning.
Is It Worth Investing in West Pharmaceutical Services, Inc (NYSE: WST) Right Now?
West Pharmaceutical Services, Inc (NYSE: WST) has a price-to-earnings ratio of 49.54x that is above its average ratio. Additionally, the 36-month beta value for WST is 1.00. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 2 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for WST is 71.99M and currently, short sellers hold a 1.62% ratio of that float. The average trading volume of WST on December 20, 2024 was 607.77K shares.
WST’s Market Performance
WST stock saw an increase of 1.18% in the past week, with a monthly gain of 7.16% and a quarterly increase of 8.88%. The volatility ratio for the week is 2.77%, and the volatility levels for the last 30 days are 2.49% for West Pharmaceutical Services, Inc (WST). The simple moving average for the past 20 days is 3.02% for WST’s stock, with a 1.46% simple moving average for the past 200 days.
Analysts’ Opinion of WST
UBS, on the other hand, stated in their research note that they expect to see WST reach a price target of $390, previously predicting the price at $350. The rating they have provided for WST stocks is “Buy” according to the report published on December 12th, 2024.
Jefferies gave a rating of “Buy” to WST, setting the target price at $536 in the report published on February 07th of the current year.
WST Trading at 5.61% from the 50-Day Moving Average
After a stumble in the market that brought WST to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -19.27% of loss for the given period.
Volatility was left at 2.49%, however, over the last 30 days, the volatility rate increased by 2.77%, as shares surge +2.99% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +13.93% upper at present.
During the last 5 trading sessions, WST rose by +0.13%, which changed the moving average for the period of 200-days by -8.74% in comparison to the 20-day moving average, which settled at $324.00. In addition, West Pharmaceutical Services, Inc saw -5.16% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at WST starting from Witherspoon Charles, who sale 703 shares at the price of $310.40 back on Oct 29 ’24. After this action, Witherspoon Charles now owns 1,253 shares of West Pharmaceutical Services, Inc, valued at $218,211 using the latest closing price.
Witherspoon Charles, the VP & Treasurer of West Pharmaceutical Services, Inc, sale 1,029 shares at $300.00 during a trade that took place back on Aug 19 ’24, which means that Witherspoon Charles is holding 1,478 shares at $308,700 based on the most recent closing price.
Stock Fundamentals for WST
Current profitability levels for the company are sitting at:
- 0.2 for the present operating margin
- 0.35 for the gross margin
The net margin for West Pharmaceutical Services, Inc stands at 0.17. The total capital return value is set at 0.18. Equity return is now at value 17.78, with 13.45 for asset returns.
Based on West Pharmaceutical Services, Inc (WST), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at 3.47. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is 115.16.
Currently, EBITDA for the company is 844.1 million with net debt to EBITDA at -0.25. When we switch over and look at the enterprise to sales, we see a ratio of 8.35. The receivables turnover for the company is 5.49for trailing twelve months and the total asset turnover is 0.78. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.00.
Conclusion
In conclusion, West Pharmaceutical Services, Inc (WST) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
